Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2-Reference-Cited by-同舟云学术

Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2

Published:2014-05-23 Issue:6 Volume:3 Page:499-507
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:

Author:

Klamerus Karen J.¹,Alvey Christine²,Li Lei¹,Feng Bo¹,Wang Rong²,Kaplan Irina²,Shi Haihong²,Dowty Martin E.³,Krishnaswami Sriram²

Affiliation:

1. Pfizer Inc; San Diego CA USA

2. Pfizer Inc; Groton CT USA

3. Pfizer Inc; Andover MA USA

Funder

Complete Medical Communications

Pfizer Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.120/fullpdf

Reference28 articles.

1. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis;Meyer;J Inflamm (Lond).,2010

2. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans;Dowty;Drug Metab Dispos.,2014

3. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: Confirmation of in vitro data;Gupta;Br J Clin Pharmacol.,2012

4. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects;Gupta;Clin Pharm Drug Dev.,2014

5. A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants;Krishnaswami;J Clin Pharmacol.,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD;Expert Review of Gastroenterology & Hepatology;2020-07-01

2. Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment;Drug Safety;2020-05-04

3. Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers;Clinical Pharmacology in Drug Development;2019-11-11

4. Clinical efficacy of new JAK inhibitors under development. Just more of the same?;Rheumatology;2019-02-01

5. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial;Arthritis Research & Therapy;2015-04-06